Protection against Plasmodium falciparum can be induced by vaccination in animal models with merozoite surface protein 1 (MSP1), which makes this protein an attractive vaccine candidate for malaria. In an attempt to produce a product that is easily scaleable and inexpensive, we expressed the C-terminal 42 kDa of MSP1 (MSP1 42 ) in Escherichia coli, refolded the protein to its native form from insoluble inclusion bodies, and tested its ability to elicit antibodies with in vitro and in vivo activities. Biochemical, biophysical, and immunological characterization confirmed that refolded E. coli MSP1 42 was homogeneous and highly immunogenic. In a formulation suitable for human use, rabbit antibodies were raised against refolded E. coli MSP1 42 and tested in vitro in a P. falciparum growth invasion assay. The antibodies inhibited the growth of parasites expressing either homologous or heterologous forms of P. falciparum MSP1 42 . However, the inhibitory activity was primarily a consequence of antibodies directed against the C-terminal 19 kDa of MSP1 (MSP1 19 ). Vaccination of nonhuman primates with E. coli MSP1 42 in Freund's adjuvant protected six of seven Aotus monkeys from virulent infection with P. falciparum. The protection correlated with antibody-dependent mechanisms. Thus, this new construct, E. coli MSP1 42 , is a viable candidate for human vaccine trials.
The malarial parasite remains a scourge on human civilization, and in recent years the incidence of malaria has been increasing (5, 25) . Vaccination against Plasmodium falciparum has the potential to reduce severe malaria-associated morbidity and mortality in areas with the most intense transmission, and it may do so without necessarily preventing blood stage infection (20, 24) . Most blood stage vaccine research has been focused on antigens that are expressed on the surface of merozoites (11) . Merozoites are released from rupturing red blood cells (RBCs) and quickly invade other RBCs. Merozoite surface protein-specific antibodies, therefore, have only a brief period of time in which they can be active (26) . The most widely studied merozoite surface protein is merozoite surface protein 1 (MSP1) (15) . This molecule is polymorphic and has a complex folding pattern (8, 21) .
P. falciparum MSP1 is a large (ϳ200-kDa) protein. MSP1 is processed into a complex of polypeptides on the merozoite surface, including an 82-kDa N-terminal polypeptide and 30-and 38-kDa central regions, as well as the 42-kDa C-terminal region (MSP1 42 ) (1) . At the time of RBC invasion, MSP1 42 is further processed by proteolytic cleavage into a 33-kDa fragment (MSP1 33 ), which is shed from the parasite with the rest of the MSP1 complex, and a C-terminal 19-kDa fragment (MSP1 19 ). Only the C-terminal MSP1 19 fragment remains on the merozoite surface and is carried into parasitized RBCs (2) . This so-called secondary processing of MSP1 is completed during the successful invasion of a RBC, suggesting that it is a necessary step (3, 7) .
The MSP1 19 and MSP1 42 regions of P. falciparum MSP1 are leading malaria vaccine candidates (15) . Studies with rodent malaria and challenge studies with P. falciparum in primates have indicated that vaccines based on MSP1 19 and MSP1 42 confer protection against malaria (6, 9, 12, 13, 29, 30) . Recently, O'Donnell et al. (22) convincingly demonstrated not only that most sera from two high-transmission areas in Papua New Guinea were able to inhibit parasite invasion in vitro but also that the inhibitory activity was primarily directed against MSP1. By constructing a chimeric transfected P. falciparum line, D-10 (D10-PcMEGF), which expressed an antigenically distinct MSP1 19 domain from the distantly related rodent species Plasmodium chabaudi, these authors showed that MSP1 19 specific antibodies comprised a large component of the total invasion-inhibiting response of sera from many P. falciparumimmune adults in Papua New Guinea (22) . There are two implications of these results that can be used for malaria vaccine development. First, antibodies specific to MSP1 19 may play a major role in reducing parasite multiplication rates during natural immunity. And second, although in animal models protection elicited with vaccines based on MSP1 requires high antibody titers, the lower levels of antibody obtainable in natural infections have an effect on in vitro parasite growth.
As a part of a strategy for malaria vaccine development based on recombinant MSP1, the following different expression systems for MSP1 production have been evaluated: Saccharomyces cerevisiae (18, 19) , Pichia pastoris (4), baculovirus-infected insect cells (29) , and milk from transgenic mice (30) . Recombinant MSP1 42 produced in baculovirus-infected insect cells (6, 29) and transgenic milk (30) elicits protective responses in an in vivo model system but has yet to be scaled up for human clinical trials. The purpose of the present study was to examine Escherichia coli expression for the production of MSP1 42 . The E. coli protein expression system, which was the first commercialized system for recombinant protein production, is cost-effective and very efficient for nonglycosylated proteins, such as MSP1 42 . MSP1 is a nonglycosylated protein in its native form, and glycosylation blocks the efficacy of MSP1 42 produced in transgenic milk (30) . Here, we describe methods to produce recombinant MSP1 42 in its correctly folded conformation, to examine the ability of antibodies raised against recombinant MSP1 42 to block erythrocyte invasion by P. falciparum in vitro, and to examine the in vivo efficacy of MSP1 42 in Aotus nancymai monkeys against a lethal challenge with P. falciparum.
MATERIALS AND METHODS
Expression and fermentation conditions for E. coli MSP1 42 . The amino acid sequence of MSP1 42 FVO (MSP1 42 of the Vietnam-Oak Knoll or FVO strain; GenBank accession no. L20092) was used to construct a synthetic gene. The coding sequence of the gene was optimized for expression in E. coli by normalizing its AT content on the basis of previously published values for E. coli codon bias. This construct, corresponding to amino acids A-1 to S-355, was generated by PCR techniques and was subcloned into a pCR-blunt vector from Invitrogen. 4 OH was the nitrogen source, and glucose was the carbon source. Fermentation was carried out at 37°C, and once the optical density at 550 nm reached 35, the culture was induced by adding isopropyl-1-thio-␤-galactopyranoside (IPTG) to a final concentration of 1 mM. Induction was continued for 3 h before harvesting by centrifugation and cell pellet storage at Ϫ80°C.
Refolding and purification of E. coli MSP1 42 . A portion of the frozen cell pellet was resuspended in 10 volumes of lysis buffer (10 mM Tris-HCl [pH 8.0], 10 mM EDTA, 100 mM NaCl, 5 mM dithiothreitol) and lysed at 19,000 lb/in 2 by using a microfluidizer (Microfluidics Corporation, Newton, Mass.). The resulting lysate was mixed with an equal volume of freshly prepared urea wash buffer (10 mM Tris-HCl [pH 8.0], 5 mM EDTA, 2 M urea, 1% Triton X-100) and stirred for 1 h at 4°C. The lysate was centrifuged for 30 min at 10,000 ϫ g, and recombinant E. coli MSP1 42 was detected in the pellet formed by inclusion bodies. The inclusion body pellet was resuspended in solubilization buffer ( The Ni-NTA column was washed with 5 column volumes of 2ϫ PBS, and protein was eluted from the column by using 1ϫ PBS containing 250 mM imidazole. Final purification of the refolded E. coli MSP1 42 eluted from the Ni-NTA was carried out by using a Superdex 75 column (Amersham Pharmacia) with PBS. Analysis of refolded E. coli MSP1 42 . Reverse-phase high-performance liquid chromatography analysis of refolded E. coli MSP1 42 was carried out with a Dynamax 300Å C 4 column (Varian Inc., Walnut Creek, Calif.). The gradient used for elution was developed from buffer A (0.1% trifluoroacetic acid in water) and buffer B (0.1% trifluoroacetic acid in 90% acetonitrile-10% water). The column was initially equilibrated with 90% buffer A and 10% buffer B and reached a composition of 10% buffer A and 90% buffer B in 75 min. N-terminal amino acid sequencing was performed by the Biological Resources Branch, National Institute of Allergy and Infectious Diseases. Protein concentrations were determined with a bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, Ill.). Electrophoresis and immunoblotting of sodium dodecyl sulfate (SDS) gels were performed by using standard methods, except that 2.5% bovine serum albumin was used to block the binding sites on nitrocellulose after protein transfer. All washes were performed in 1ϫ PBS containing 0.02% Tween 20 and 0.2% Triton X-100. For development of the blot, the nitrocellulose was treated with a 1:1,000 dilution of five individual conformation-specific monoclonal antibodies raised against baculovirus MSP1 42 FVO (13) . The primary antibody was detected with goat anti-mouse alkaline phosphatase-conjugated secondary antibody (Kirkegard and Perry, Gaithersburg, Md.). Detection was performed by using a 5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium colorimetric kit (Kirkegaard and Perry).
Preparation of rabbit antisera against E. coli MSP1 42 . Rabbit antisera against recombinant refolded E. coli MSP1 42 were raised by immunization with 50 g of the antigen emulsified in 100 l of Montanide ISA 720 (SEPPIC, Fairfield, N.J.). The primary immunization was intramuscular (zero time), and subsequent immunizations were subcutaneous (days 21 and 42). Sera were collected on days 42 and 63. Each rabbit serum was heat inactivated at 56°C for 20 min and then sterilized by filtration through a 0.22-m-pore-size filter.
Parasite culture and GIA. The following P. falciparum culture-adapted clones were used for growth inhibition assays (GIAs): P. falciparum FVO (27) , D10-PfM3Ј (Pf-D10), and chimeric parasite D10-PcMEGF (Pf-D10Pc) (22) . The chimeric parasite Pf-D10Pc is identical to the parental Pf-D10 clone except that the Pf-D10 MSP1 19 domain is replaced by the domain from P. chabaudi. Prior to use, each clone was cultured by using standard techniques but was preadapted to grow in 25% normal rabbit serum without a loss of viability. The GIA employed is a reproducible method developed in our laboratory (17) . Percentages of inhibition were determined by using the following formula: 100 Ϫ {[(A 650 of immune sample Ϫ A 650 of RBC alone)/(A 650 of preimmune control Ϫ A 650 of RBC alone)] ϫ 100}.
Vaccination and challenge infection of malaria-naive Aotus monkeys. Fourteen monkeys were randomly assigned to two groups containing seven monkeys each. One vaccine group received E. coli MSP1 42 , and the control group received an unrelated recombinant Plasmodium vivax antigen, Pvs25H, as a negative control.
The monkeys received three vaccinations consisting of 100 g of E. coli MSP1 42 or Pvs25H emulsified in 400 l of the adjuvant 3 weeks apart, as described previously (29) . The initial vaccination preparations were emulsified with complete Freund's adjuvant (Sigma, St. Louis, Mo.), and the subsequent two vaccination preparations were emulsified with Montanide ISA 51. Sera were collected from the vaccinated monkeys on day 15 after the third vaccination, and then the monkeys were challenged by intravenous injection of 5 ϫ 10 4 infected RBCs from a donor monkey infected with the highly virulent P. falciparum FVO strain. Parasitemia was monitored daily by examining Giemsa-stained thin films until treatment. The monkeys were treated when the parasitemia reached Ͼ4.5% or the hematocrit fell below 25%. All monkeys not treated previously were treated on day 28 after challenge. The treatment consisted of mefloquine administered in a single dose of 25 mg/kg of body weight by intubation.
Measurement of antibody responses. Enzyme-linked immunosorbent assays (ELISAs) and indirect immunofluorescence assays were performed as previously described (21) . Serum dilutions that gave an absorbance that was 0.5 U above the background value were designated the endpoint of the ELISA titer.
Statistical methods. Aotus monkeys that control their parasitemia (i.e., the parasitemia remains less than 4.5%) either self-cure or suffer from anemia and require treatment. At this point it is impossible to say what would have occurred to a monkey's parasite burden; the monkey may have self-cured, continued to control the parasitemia, or lost control and suffered from a virulent infection. Thus, the primary endpoint data included only data collected until the first monkey was treated for anemia rather than parasitemia. At that time, all monkeys were ranked in the following order. Monkeys that were treated for parasitemia prior to the day of data collection were ranked first, in order of the first day of treatment and then cumulative parasitemia (the sum of a monkey's daily parasite burden). Then the monkeys that required treatment for low hematocrit (thus triggering the endpoint) were ranked in the same fashion. Finally, monkeys that did not require treatment until that point were ranked in order of their cumulative parasitemias (29) . A nonparametric, unpaired Mann-Whitney U test was then performed to compare the test group to the control group. Secondary statistical comparisons were also made. Nonlinear Spearman's regression analysis was performed to correlate antibody responses to protection from challenge. Unpaired Mann-Whitney U tests were also used to compare data between the vaccine groups (e.g., days until patent).
RESULTS
Expression, in vitro refolding, and purification of E. coli MSP1 42 . Fermentation of E. coli BL21(DE3) cells containing the pPfMSP1 42 FVOPET plasmid in defined medium showed that there was time-dependent accumulation of a ϳ42-kDa protein when the preparation was induced with IPTG (Fig.  1A) . Based on an SDS-polyacrylamide gel electrophoresis (PAGE) analysis and light microscopy, expression of recombi- nant E. coli MSP1 42 was associated with the insoluble fraction of the cell lysate in the form of inclusion bodies. The recombinant E. coli MSP1 42 was isolated from the inclusion bodies by solubilization in denaturant and reductant buffer, followed by rapid dilution in refolding buffer. Refolded E. coli MSP1 42 was further purified by using three stringent chromatography purification processes involving three different chemistries. This purification yielded a homogeneous product. As determined by SDS-PAGE, the refolded E. coli MSP1 42 had an observed molecular mass under nonreducing conditions of ϳ39 kDa, and the molecular mass under reducing conditions was ϳ42 kDa (Fig. 1B) . Densitometry scanning of the Coomassie bluestained gel indicated that the purity of the refolded and purified E. coli MSP1 42 was more than 94%. The homogeneity of the refolded and purified E. coli MSP1 42 was analyzed by reverse-phase high-performance liquid chromatography, which can separate different conformers of a protein based on the change in surface hydrophobicity. Refolded E. coli MSP1 42 eluted in a single peak during reverse-phase chromatography on a C 4 column (Fig. 1C) , suggesting that purified E. coli MSP1 42 is homogeneous. N-terminal sequencing of the refolded E. coli MSP1 42 yielded the expected sequence (AVTPSVIDNILSKIE) with successful cleavage of the bacterial N-formyl methionine. The mobilities of reduced and nonreduced samples of naturally refolded and purified recombinant baculovirus MSP1 42 and refolded E. coli MSP1 42 on SDS-PAGE gels were compared (Fig. 2A) . The shifts in mobility after reduction appeared to be similar, although baculovirus MSP1 42 migrated more slowly than refolded E. coli MSP1 42 under both nonreduced and reduced conditions. This slower migration resulted from the glycosylation of the baculovirus MSP1 42 (29) . Immunological characterization was performed by using conformation-specific monoclonal antibodies and a positive control (baculovirus MSP1 42 ). All five conformation-specific monoclonal antibodies reacted with nonreduced E. coli MSP1 42 but not with reduced E. coli MSP1 42 . An example of the reactivity pattern is shown in Fig. 2B . Monoclonal antibody bv223 reacted with nonreduced refolded E. coli MSP1 42 and baculovirus MSP1 42 identically and did not react with the reduced samples.
Elicitation of an immune response known to occur in natural infections. A vaccine formulation suitable for human use (10) was prepared by using the E. coli MSP1 42 protein (50 g of protein emulsified in 100 l of Montanide ISA 720). This formulation was used to immunize rabbits, and the immune sera were tested for inhibition of the growth of P. falciparum parasites in vitro. Immune sera from all four rabbits had high titers (Fig. 3A) and effectively blocked parasite invasion by the P. falciparum FVO laboratory clone (homologous to the immunogen) in a concentration-dependent manner (Fig. 3B) . These data suggest that at whole-blood concentrations (effectively 100% serum), parasite growth inhibition would have been total.
To examine heterologous parasite growth inhibition, Pf-D10 was used in the GIA. Figure 4 shows alignments of the sequences of the P. falciparum FVO and Pf-D10 MSP1 proteins for both the MSP1 33 (Fig. 4A ) and MSP1 19 (Fig. 4B) . Pooled immune rabbit sera at a concentration of 20% inhibited the growth of the heterologous parasite Pf-D10 significantly (58% inhibition). However, this level of inhibition was significantly lower than the level of inhibition of the homologous parasite P. falciparum FVO (P ϭ 0.033, as determined by a paired Student's t test at a serum concentration of 20%).
To investigate whether the significant inhibition of the Pf-D10 parasite was due to growth-inhibitory antibodies directed against the C-terminal MSP1 19 or the N-terminal MSP1 33 domain of MSP1 42 , the GIA was repeated with the parasite line Pf-D10Pc. Pf-D10Pc is identical to the parental clone, Pf-D10, in the MSP1 33 region, but the MSP1 19 domain is replaced by the domain from P. chabaudi. (Fig. 4) . No inhibitory effect on Pf-D10Pc parasite growth was observed (Fig. 5) .
E. coli MSP1 42 was used to vaccinate A. nancymai monkeys (n ϭ 7), which were examined in conjunction with control animals (n ϭ 7) that received the irrelevant negative control antigen Pvs25H. Fifteen days after the third vaccination all monkeys were challenged with 5 ϫ 10 4 P. falciparum FVO parasites. The primary technique used to measure efficacy was to rank animals in order of treatment for parasitemia and cumulative parasitemia at the time that the first monkey was treated for anemia, day 18 (see Materials and Methods). Refolded E. coli MSP1 42 was found to be efficacious, and the cumulative parasitemias were significantly less than those of the control animals ( Fig. 6 ) (P Ͻ 0.01). By day 18, one of the seven animals in the E. coli MSP1 42 group had been treated for parasitemia of Ͼ4.5%, compared with six of the seven animals in the control vaccine group. On day 18, four animals were treated for anemia; three of these animals were in the E. coli MSP1 42 group, and the other animal was in the Pvs25H group.
Other secondary markers of protection confirmed these results (Table 1 ). E. coli MSP1 42 -immunized monkeys were significantly different from control animals when the numbers of days to patency, the numbers of days to treatment, the numbers of days to peak parasitemia, and the actual peak parasitemia values were compared (P ϭ 0.04, P ϭ 0.02, P ϭ 0.008, and P ϭ 0.03, respectively, as determined by the Mann-Whitney U test). Overall, six of seven control group animals required treatment for parasitemia of Ͼ4.5%. One of the seven E. coli MSP1 42 -immunized animals required treatment for parasitemia, one animal self-cured, and five animals controlled the parasitemia but required treatment for a decrease in hematocrit to Ͻ25%. ELISA titers (against the reference antigen baculovirus MSP1 42 ) for the vaccinated monkeys are shown in Table 1 . Overall, the antibody titers correlated with protection. There was a significant correlation between the antibody titers to E. coli MSP1 42 and the primary outcome of protection (P ϭ 0.0004; Spearman rank r ϭ Ϫ0.79).
DISCUSSION
We describe a method used to produce from an E. coli expression system a recombinant E. coli MSP1 42 that was purified from inclusion bodies and refolded by oxidative rapid dilution. A variety of biochemical, biophysical, and immunological assays were used to demonstrate that the refolded E. coli MSP1 42 is homogeneous and immunogenic. First, refolded E. coli MSP1 42 eluted in a single peak during reverse-phase chromatography on a C 4 column, suggesting that it is composed of a homogeneous population of conformers. Second, E. coli MSP1 42 exhibited a reduction-sensitive shift in mobility during SDS-PAGE, suggesting that disulfide bonds were formed. Third, recombinant MSP1 42 has been expressed previously in its functional form as a secreted protein in insect cells by using baculovirus vectors (29) . The reactivity of E. coli MSP1 42 with conformation-specific monoclonal antibodies is similar to the reactivity of the naturally refolded baculovirus MSP1 42 . Recombinant proteins expressed as secreted proteins in eukaryotic cells are commonly glycosylated. This may be relevant for immunogenicity of vaccine candidate antigens, as previous studies demonstrated that a glycosylated form of MSP1 42 expressed in transgenic mouse milk did not induce a protective response against malaria (30) , while the glycosylated form of MSP1 42 produced in baculovirus was protective. These differences may be due to the type of glycosylation and the extent of glycosylation on molecules produced in the two different expression systems (30) . E. coli is thus well suited for the production of nonglycosylated malarial parasite antigens as vaccine candidates (23, 28) , and in this report we provide the first description of methods developed for refolding and purification of functional E. coli MSP1 42 produced in a bacterial expression system.
Immunization of rabbits with E. coli MSP1 42 elicits antibod- The data suggest that the target of the antibodies raised against E. coli MSP1 42 that block invasion of human erythrocytes is MSP1 19 . This was shown by comparing the inhibition data for two identical parasites that differ only in the replacement of MSP1 19 of P. falciparum by MSP1 19 of P. chabaudi (Pf-D10 and Pf-D10Pc) (Fig. 4) . Invasion by the P. chabaudi chimera (Pf-D10Pc) was not inhibited, whereas the level of inhibition for the parasite with the P. falciparum sequence (Pf-D10) was around 58% (Fig. 5) .
Polymorphisms at four amino acid positions in MSP1 19 were identified when the FVO and 3D7 sequences were compared (21) . These differences may have been selected to minimize cross-protection. We found in the present study that sera raised against the P. falciparum FVO sequence (E. coli MSP1 42 ) inhibited invasion of RBCs by the Pf-D10 parasite, which differs from FVO at these four amino acid residues. Similar results were described previously (16); antibodies against parasites that differed at these four amino acids could cross-inhibit, although, as in our study, the inhibition appeared to be less than the inhibition observed with the homologous strain. In another study, however, in which a competitive ELISA with heterologous MSP1 19 domains was used, some rabbit sera exhibited no cross-reaction with the heterologous recombinant protein (29) . Thus, despite the cross-inhibition in rabbits in the two studies, the lack of cross-reactions in other rabbits may indicate that both types of sequences are required in a vaccine.
Immunization with E. coli MSP1 42 elicits high-titer antibodies in Aotus monkeys and leads to significant protection against a lethal P. falciparum in vivo challenge. A strong correlation between protection and antibody titers was observed, and the variation in protection between animals can be accounted for by variation in the antibody titers (P ϭ 0.0004; Spearman rank r ϭ Ϫ0.79). These findings are in accordance with recent data from rodent malaria models, in which protection is also antibody dependent (31, 32) . In three previous independent studies of baculovirus MSP1 42 -immunized Aotus monkeys, a consistent pattern of protection was observed with six of seven animals (29) , five of seven animals (14) , and five of seven animals (30) . In the control groups all four animals (29), five of seven animals (14) , and six of seven animals (30) developed virulent infections. In the present study E. coli MSP1 42 protected six of seven monkeys, while six of seven monkeys in the control group developed virulent infections and required treatment for parasitemia. Therefore, we concluded that the E. coli MSP1 42 efficacy in the protection study was indistinguishable from that previously seen with baculovirus MSP1 42. In conclusion, immunization with E. coli MSP1 42 induces protective efficacy, and at least one of the probable effector mechanisms of that efficacy (as determined by an antibody-dependent growth inhibition assay) is a mechanism thought to be instrumental in natural immunity.
As a part of an overall strategy for malaria vaccine development based on recombinant MSP1, the following five different expression systems have been evaluated for MSP1 production: S. cerevisiae (18, 19) , P. pastoris (4), baculovirus-infected insect cells (29) , transgenic milk (30) , and E. coli (this study). We concluded that E. coli is the optimal expression system. Both of the yeast systems failed to make full-length MSP1 42 , and the efficacy of the smaller MSP1 19 fragment was less consistent (29) . Although the efficacies of baculovirus-expressed MSP1 42 , transgenic MSP1 42 , and E. coli MSP1 42 appear to be indistinguishable, the yields of E. coli MSP1 42 are superior to those of baculovirus MSP1 42 (ϳ30 mg/liter, compared to ϳ8 mg/liter), and the E. coli MSP1 42 development time frame is greatly reduced. As an example of the latter finding, we have been able to successfully manufacture cGMP grade material for human clinical trials of not just the FVO allele of E. coli MSP1 42 discussed here but also the alternate 3D7 allele (S. Singh and A. Stowers, unpublished data). Thus, the new construct, E. coli MSP1 42 , is a viable candidate for human vaccine trials. 
